Loading
Life sciences · Journal article
Acs Omega · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Pancreatic cancer represents one of the most lethal cancers, characterized by poor survival rates and persistent therapeutic resistance. In this study, we investigated the anticancer potential and underlying mechanism of SNU523 (8-O-demethyl-9,11-didechloropestalone), a compound isolated from the marine-derived fungus Pestalotiopsis neglecta. SNU523 exhibited potent antiproliferative effects, reduced colony formation in PDAC cells, and suppressed tumor growth in a xenograft model. SNU523 demonstrated dual inhibitory activity against the STAT3 and MEK signaling pathways, suggesting the potential for overcoming therapeutic resistance driven by the inverse interplay between these cascades. This dual suppression may be attributed to its modulatory effects on the epidermal growth factor receptor (EGFR) protein and mRNA levels. Taken together, these findings suggest that SNU523 represents a highly promising candidate for targeted therapy against pancreatic cancer, and it merits extensive investigation in both preclinical and clinical settings.